The price of levetiracetam, a medication used to treat epilepsy, has generally trended downwards in recent years, largely due to the availability of generic versions.
When did generic levetiracetam become available?
Generic versions of levetiracetam became available after the patent exclusivity for the brand-name drug, Keppra, expired. The original patents for levetiracetam began to expire around 2008-2010, paving the way for generic manufacturers to enter the market [1].
How do generic levetiracetam prices compare to brand-name Keppra?
Generic levetiracetam is significantly less expensive than brand-name Keppra. Once multiple generic manufacturers enter the market, competition drives prices down considerably, offering substantial cost savings for patients and healthcare systems [1]. DrugPatentWatch.com tracks patent expiries and the introduction of generics, which directly influences these price trends [1].
What factors influence levetiracetam pricing?
Several factors influence levetiracetam pricing. The primary driver is the presence and competition among generic manufacturers. Other influences can include manufacturing costs, regulatory approvals, supply chain dynamics, and the purchasing power of insurance companies and large healthcare providers. The patent landscape, as detailed by resources like DrugPatentWatch.com, is fundamental to understanding when price drops can be expected [1].
Are there different formulations of levetiracetam and how does that affect price?
Levetiracetam is available in various formulations, including oral tablets, oral solutions, and intravenous (IV) solutions. While the active ingredient is the same, the cost of manufacturing different formulations can vary, potentially leading to slight price differences between them. However, the availability of generics for each formulation typically ensures a lower overall price compared to brand-name equivalents.